---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-073421"
form_type: "8-K"
ticker: "VERA"
cik: "0001831828"
company_name: "Vera Therapeutics, Inc."
filed_at: "2026-02-26T23:59:59+00:00"
generated_at: "2026-05-15T23:46:44.640463+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Vera Therapeutics reports FY 2025 net loss $299.6M; FDA priority review for atacicept PDUFA July 7, 2026

## Summary
- Net loss of $299.6M (diluted EPS -$4.66), vs $152.1M loss in FY 2024.
- Cash, equivalents, and marketable securities $714.6M as of Dec 31, 2025, expected to fund through atacicept launch.
- FDA granted priority review for atacicept BLA in IgA nephropathy; PDUFA date July 7, 2026.
- Completed $800M equity/debt financings; potential U.S. commercial launch mid-2026 if approved.
- Appointed James R. Meyers to Board; Phase 2 PIONEER basket trial results expected 1H 2026.

## SEC filing metadata
- accession: 0001193125-26-073421
- form_type: 8-K
- ticker: VERA
- cik: 0001831828
- company_name: Vera Therapeutics, Inc.
- filed_at: 2026-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831828/000119312526073421/0001193125-26-073421-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831828/000119312526073421/vera-20260226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-073421
- JSON: https://secwatch.observer/filing/0001193125-26-073421.json
- Plain text: https://secwatch.observer/filing/0001193125-26-073421.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.